Media & Resources

The International AIDS Vaccine Initiative (IAVI) announces an expanded partnership with Oxford University to develop a broadly effective AIDS vaccine candidate.

The International AIDS Vaccine Initiative (IAVI) is sponsoring a Phase 1 clinical trial (T001) led by the Beth Israel Deaconess Medical Center (BIDMC) to investigate the safety and tolerability of a broadly neutralizing antibody infusion (bNAb) to prevent HIV infection. A maximum of 93 volunteers will receive one-time infusions of the bNAb PGT121 at varying…

The International AIDS Vaccine Initiative (IAVI) has recently been awarded two new grants by the Bill & Melinda Gates Foundation to expedite the development of promising AIDS vaccine candidates and other new biomedical HIV prevention tools. The grants provide for funding in an amount of almost US$60M over three and a half years. Under these…

New approaches that could spur the human body to produce HIV-blocking antibodies have been successful in mice mimicking the human immune system, according to five studies published today in the research journals Cell, Immunity and Science. The results were produced by scientists affiliated with the International AIDS Vaccine Initiative (IAVI); The Scripps Research Institute (TSRI);…

IAVI to ensure characterization and manufacturing of AIDS vaccine immunogens.

Board member Lord Norman Fowler elected Lord Speaker for the United Kingdom’s House of Lords.

Africa-centered global partnership will advance pre-clinical and clinical AIDS vaccine research, strengthen local capacity and ownership and support sustainable development of African countries.

UN High Level Meeting highlights successes and continued needs in the global fight for a world without AIDS.